Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342] Draft guidance Technology appraisal guidance 6 February 2025 Capivasertib with fulvestrant ...

In England, obesity affects around 1 in 4 adults, and almost 1 in 4 children by the time they are 11, and many more people are living with overweight. Overweight and obesity can cause people ...

NICE has developed tools and resources, in association with relevant stakeholders, to help organisations put this guidance into practice. The evidence generation plan gives further information on the ...

Not relevant to current service structure of integrated commissioning boards, and now covered by government guidance on whole systems approach to obesity and the obesity framework.

Companies should work with providers and central NHS England teams to begin the research. Planning for a prespecified period for the set-up of the technologies is advised. The following considerations ...

This topic was considered by the diagnostics advisory committee, which is a standing advisory committee of NICE. Committee members are asked to declare any interests in the technologies to be ...

If data collection is expected to end later than planned, the companies should contact NICE to arrange an extension to the evidence generation period. NICE reserves the right to withdraw the guidance ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

People have the right to be involved in discussions and make informed decisions about their care, as described in NICE's information on making decisions about your care. Making decisions using NICE ...